<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17480" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Amphotericin B</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Noor</surname>
            <given-names>Asif</given-names>
          </name>
          <aff>Winthrop University Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Preuss</surname>
            <given-names>Charles V.</given-names>
          </name>
          <aff>University of South Florida</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Asif Noor declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Charles Preuss declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17480.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Amphotericin B deoxycholate, an esteemed member of the polyene class of antifungals, has&#x000a0;been a cornerstone in therapy against invasive fungal infections for over&#x000a0;5 decades. This drug has witnessed significant advancements by introducing novel lipid formulations that exhibit a reduced nephrotoxic profile compared to the traditional formulation. This comprehensive activity is designed to meticulously elucidate the indications, contraindications, pharmacological activity, adverse events, and toxicity associated with amphotericin B, equipping members of the interprofessional healthcare team with essential insights for adeptly managing mycotic infections in diverse clinical settings. Participants gain a profound understanding of the antifungal applications of amphotericin B, empowering them to contribute effectively to the collaborative care of patients grappling with fungal infections.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the appropriate indications for amphotericin B therapy based on the type of fungal infection and patient characteristics.</p></list-item><list-item><p>Implement proper dosing and administration strategies for amphotericin B to ensure optimal therapeutic outcomes while minimizing toxicity.</p></list-item><list-item><p>Assess the patient's response to amphotericin B therapy by regularly monitoring clinical symptoms, laboratory parameters, and adverse effects.</p></list-item><list-item><p>Determine a plan&#x000a0;with other healthcare professionals, such as infectious disease specialists and pharmacists, to optimize amphotericin B therapy and ensure comprehensive patient care.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17480&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17480">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17480.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Amphotericin B&#x000a0;deoxycholate belongs to the polyene class of antifungals.&#x000a0;The drug is also known as amphotericin B and has been used to treat invasive fungal infections for&#x000a0;over 50 years. Amphotericin B was first isolated as a natural product of a soil <italic toggle="yes">Actinomycete </italic>species.<xref ref-type="bibr" rid="article-17480.r1">[1]</xref><xref ref-type="bibr" rid="article-17480.r2">[2]</xref></p>
        <p>Newer lipid formulations that are less nephrotoxic than conventional amphotericin B&#x000a0;are available.<xref ref-type="bibr" rid="article-17480.r3">[3]</xref> These include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Amphotericin B liposomal, which is a liposomal formulation and exhibits increased tolerability and a reduced toxicity profile</p>
          </list-item>
          <list-item>
            <p>An amphotericin B lipid complex (ABLC) in which amphotericin B&#x000a0;is tightly packed&#x000a0;in a&#x000a0;ribbon-like structure</p>
          </list-item>
          <list-item>
            <p>Amphotericin B cholesteryl sulfate complex</p>
          </list-item>
        </list>
        <p>These lipid formulations permit a higher daily dose, provide better delivery to organs within the reticular endothelial system such as the lungs, liver, and spleen, have similar efficacy to conventional amphotericin B, and are&#x000a0;less nephrotoxic.<xref ref-type="bibr" rid="article-17480.r4">[4]</xref></p>
        <p>With the advancement of newer antifungals, such as azoles (eg, voriconazole) and echinocandins (eg, caspofungin), amphotericin B&#x000a0;is typically only reserved for selected invasive fungal infections.&#x000a0;</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>FDA-approved indications of&#x000a0;amphotericin B deoxycholate are listed below:</p>
        <list list-type="bullet">
          <list-item>
            <p>Aspergillosis</p>
          </list-item>
          <list-item>
            <p>Cryptococcosis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Severe&#x000a0;blastomycosis</p>
          </list-item>
          <list-item>
            <p>Systemic candidiasis (effective against&#x000a0;<italic toggle="yes">Candida albicans</italic>,&#x000a0;<italic toggle="yes">Candida krusei</italic>,&#x000a0;<italic toggle="yes">Candida tropicalis</italic>, and&#x000a0;<italic toggle="yes">Candida parapsilosis)</italic></p>
          </list-item>
          <list-item>
            <p>Coccidioidomycosis</p>
          </list-item>
          <list-item>
            <p>Histoplasmosis (disseminated disease)</p>
          </list-item>
          <list-item>
            <p>Zygomycosis (including mucormycosis) due to susceptible&#x000a0;<italic toggle="yes">Absidia</italic>,&#x000a0;<italic toggle="yes">Mucor</italic>, and&#x000a0;<italic toggle="yes">Rhizopus</italic>&#x000a0;<italic toggle="yes">spp species.</italic></p>
          </list-item>
          <list-item>
            <p>Infections due to related susceptible species of&#x000a0;<italic toggle="yes">Conidiobolus</italic>&#x000a0;and&#x000a0;<italic toggle="yes">Basidiobolus</italic></p>
          </list-item>
          <list-item>
            <p>Severe cases of sporotrichosis&#x000a0;<xref ref-type="bibr" rid="article-17480.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>Liposomal amphotericin B has been FDA-approved for the following indications:</p>
        <list list-type="bullet">
          <list-item>
            <p>Empirical therapy for fungal infection in febrile, neutropenic patients.</p>
          </list-item>
          <list-item>
            <p>Treatment of infections caused by refractory&#x000a0;<italic toggle="yes">Aspergillus</italic>, C<italic toggle="yes">andida</italic>, and&#x000a0;<italic toggle="yes">Cryptococcus&#x000a0;species</italic>&#x000a0;that are unresponsive to amphotericin B deoxycholate or in cases where renal impairment or unacceptable toxicity prohibits the use of amphotericin B deoxycholate.</p>
          </list-item>
          <list-item>
            <p>Visceral leishmaniasis (higher relapse rates&#x000a0;in immunocompromised patients)</p>
          </list-item>
          <list-item>
            <p>Cryptococcal<italic toggle="yes">&#x000a0;</italic>meningitis in patients with HIV&#x000a0;<xref ref-type="bibr" rid="article-17480.r6">[6]</xref></p>
          </list-item>
        </list>
        <p>Amphotericin B lipid complex (ABLC) has received FDA approval for treating invasive fungal infections in patients&#x000a0;who have shown resistance to or intolerance of conventional amphotericin B therapy.</p>
        <p>According to the IDSA (Infectious Diseases Society of America), amphotericin B deoxycholate and lipid&#x000a0;formulations are recommended for treating&#x000a0;<italic toggle="yes">aspergillus</italic>&#x000a0;infections when voriconazole is not feasible. Amphotericin B deoxycholate is suitable for resource-limited settings, while lipid formulations are preferred in cases of azole intolerance or contraindication.</p>
        <p>Aerosolized amphotericin B can be used as a prophylactic measure in specific patient populations, such as those with prolonged neutropenia, patients undergoing induction/reinduction therapy for acute leukemia, recipients of allogeneic hematopoietic stem cell transplantation during conditioning or graft-vs-host disease treatment and lung transplant recipients.<xref ref-type="bibr" rid="article-17480.r7">[7]</xref>&#x000a0;</p>
        <p>IDSA guidelines endorse amphotericin B for visceral&#x000a0;and cutaneous leishmaniasis.<xref ref-type="bibr" rid="article-17480.r8">[8]</xref>&#x000a0;A lipid formulation of amphotericin B for candidemia is a reasonable alternative for intolerance, limited availability, or resistance to other antifungal agents. For chorioretinitis with vitreous, intravitreal amphotericin B deoxycholate should be considered. Cystitis due to&#x000a0;<italic toggle="yes">Candida&#x000a0;</italic><italic toggle="yes">glabrata</italic>&#x000a0;or&#x000a0;<italic toggle="yes">Candida</italic><italic toggle="yes">&#x000a0;krusei</italic>&#x000a0;can be treated with endoscopic lesion removal and amphotericin B bladder irrigation.<xref ref-type="bibr" rid="article-17480.r9">[9]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Off-label indications for amphotericin B include severe paracoccidioidomycosis (South American blastomycosis).<xref ref-type="bibr" rid="article-17480.r10">[10]</xref>&#x000a0;Liposomal amphotericin B demonstrates effectiveness against filamentous fungi, including <italic toggle="yes">Fusarium</italic> spp., <italic toggle="yes">Scopulariopsis</italic> spp., and&#x000a0;<italic toggle="yes">Penicillium</italic> spp.<xref ref-type="bibr" rid="article-17480.r11">[11]</xref>&#x000a0;</p>
        <p>When prescribing amphotericin B, the clinician should consider the indication, the patient's immune status, and the adverse effect profile. Amphotericin is used in cerebral cryptococcosis along with flucytosine for induction therapy. Also, the resistance to amphotericin B remains low for <italic toggle="yes">Candida</italic> species except for <italic toggle="yes">Candida lusitaniae,</italic>&#x000a0;<italic toggle="yes">Aspergillus spp,</italic>&#x000a0;and opportunistic molds have a more variable susceptibility pattern.</p>
        <p>Secondary resistance is uncommon and is not usually a clinical problem.&#x000a0;Clinicians should consider in vitro susceptibility testing in cases of clinical failure and&#x000a0;when treating pathogens such as <italic toggle="yes">Candida&#x000a0;lusitaniae</italic>, <italic toggle="yes">Trichosporon</italic> species, <italic toggle="yes">Fusarium</italic> species, or <italic toggle="yes">Psudoallescheria boydii</italic>.</p>
        <p>Clinicians should recall that amphotericin B&#x000a0;exerts a concentration-dependent fungicidal activity against susceptible fungi such as <italic toggle="yes">Candida spp</italic>, <italic toggle="yes">Cryptococcus spp</italic>, and <italic toggle="yes">Aspergillus</italic>
<italic toggle="yes">spp</italic>. Amphotericin-B has been extensively used&#x000a0;COVID-19 associated mucormycosis.<xref ref-type="bibr" rid="article-17480.r12">[12]</xref></p>
      </sec>
      <sec id="article-17480.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Amphotericin B&#x000a0;acts by binding to ergosterol in the cell membrane of most fungi.&#x000a0;After binding with ergosterol,&#x000a0;amphotericin B causes the formation of&#x000a0;ion channels, leading to the loss of protons and monovalent cations, which results in depolarization and concentration-dependent cell&#x000a0;killing.<xref ref-type="bibr" rid="article-17480.r13">[13]</xref><xref ref-type="bibr" rid="article-17480.r14">[14]</xref></p>
        <p>Additionally, amphotericin B produces oxidative damage to the cells by forming free radicals and subsequently increased membrane permeability. Additionally, amphotericin B has a stimulatory effect on phagocytic cells,&#x000a0;which assists&#x000a0;in fungal infection clearance.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Amphotericin B is given parenterally due to poor oral absorption.&#x000a0;The pharmacokinetics of amphotericin B lipid complex and amphotericin B liposomal&#x000a0;are&#x000a0;non-linear, characterized by a dose-dependent increase in the volume of distribution and clearance.&#x000a0;Amphotericin B demonstrates concentration-dependent fungicidal activity and post-antifungal effect.<xref ref-type="bibr" rid="article-17480.r15">[15]</xref></p>
        <p><bold>Distribution:</bold> Amphotericin B achieves high concentrations in tissues such as the liver, spleen, bone marrow, kidneys, and lungs.&#x000a0;The amphotericin B lipid complex has&#x000a0;a higher volume of distribution than liposomal amphotericin B due to its uptake by the reticuloendothelial system. Although concentrations in cerebrospinal fluid (CSF) are low (5% of serum), it is effective in the treatment of fungal infections of the central nervous system (CNS) when given intrathecally (higher risk of toxicity).&#x000a0;A high interindividual variability characterizes the reported pharmacokinetic data in children. Children seem to clear the drug from plasma more rapidly than adults. Liposomal amphotericin B&#x000a0;achieves higher concentrations in the blood, liver, and spleen but lower levels in the kidneys and lungs compared to conventional formulations. The plasma protein binding of amphotericin B is approximately 90%.<xref ref-type="bibr" rid="article-17480.r16">[16]</xref></p>
        <p><bold>Metabolism:</bold> According to the current evidence, amphotericin B is not metabolized in the liver. The primary route of elimination for amphotericin B is through the kidneys.<xref ref-type="bibr" rid="article-17480.r17">[17]</xref></p>
        <p><bold>Elimination:</bold>&#x000a0;The kidneys gradually eliminate conventional amphotericin B, with only a small percentage (2% to 5%) of the dose excreted in its active form over a prolonged period. Liposomal amphotericin B is primarily eliminated from the body through unchanged excretion in feces and urine, with less than 10% of the administered dose being excreted over 7 days. The amphotericin B lipid complex (ABLC) excretion in urine over 24 hours amounts to approximately 0.9% of the administered dose. The clearance of amphotericin B lipid complex and liposomal amphotericin B follows non-linear kinetics, with&#x000a0;a dose-dependent&#x000a0;increase in the elimination of the drug.<xref ref-type="bibr" rid="article-17480.r11">[11]</xref></p>
      </sec>
      <sec id="article-17480.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Amphotericin B is amphoteric (can act as both an acid and a base) and water-insoluble.&#x000a0;The drug is not absorbable via oral or intramuscular administration.<xref ref-type="bibr" rid="article-17480.r18">[18]</xref></p>
        <p>
<bold>Dosage and Strengths</bold>
</p>
        <p>The recommended daily dose depends upon the type of infection, the organ involved, and the host (immunocompetent versus immunocompromised) and ranges from 0.7 to 1 mg/kg per day over 2 to 4 hours, as tolerated.</p>
        <p>Amphotericin B intravenous (IV) infusion administration occurs over 2 to 6 hours.&#x000a0;If the patient experiences fever, hypertension, chills, or nausea, premedication 30 to 60 minutes before administration with a combination of acetaminophen/ibuprofen plus diphenhydramine and hydrocortisone should merit consideration. The risk of nephrotoxicity increases at doses greater than 1 mg/kg, and no evidence supports doses greater than 1.5 mg/kg/d (amphotericin B deoxycholate). Pretreating the patient with 1&#x000a0;L of normal saline can attenuate nephrotoxicity.</p>
        <p><bold>Amphotericin B deoxycholate:</bold> The recommended dosage is 0.5 to 1 mg/kg/d. The maximum recommended dose is 1.5 mg/kg/d.</p>
        <p><bold>Amphotericin B lipid complex (ABLC):</bold> The recommended dosage is 5 mg/kg/d.</p>
        <p><bold>Liposomal amphotericin B:</bold>&#x000a0;For empirical therapy, the initial dose is 3 mg/kg/d. In systemic fungal infections caused by <italic toggle="yes">Aspergillus</italic>, <italic toggle="yes">Candida</italic>, and <italic toggle="yes">Cryptococcus</italic>, the initial dose ranges from 3 to 5 mg/kg/d. In the case of cryptococcal meningitis in HIV-infected patients, the recommended initial dose is 6 mg/kg/d.<xref ref-type="bibr" rid="article-17480.r19">[19]</xref></p>
        <p><bold>Mucormycosis:</bold>&#x000a0;Amphotericin B and its lipid formulations, including liposomal amphotericin and the amphotericin lipid complex, are superior to conventional amphotericin for treating mucormycosis. For COVID-19-associated mucormycosis, liposomal&#x000a0;amphotericin&#x000a0;(5 mg/kg/d) is the preferred treatment. A high dose of liposomal amphotericin or the amphotericin lipid complex (10 mg/kg/d) is recommended for CNS involvement or solid organ transplant recipients. The continuation of high-dose treatment is appropriate for stable or partially responsive cases, while the progressive disease may require combination therapy with liposomal amphotericin with posaconazole. In cases of treatment-related toxicity, a low dose of liposomal amphotericin or the amphotericin lipid complex (5 mg/kg/d) is recommended. In resource-limited settings,&#x000a0;amphotericin B deoxycholate can be used.<xref ref-type="bibr" rid="article-17480.r20">[20]</xref></p>
        <p>Topical use of amphotericin B for&#x000a0;peritoneal&#x000a0;or&#x000a0;bladder wash has been reported in the literature but is not recommended. Topical amphotericin B irritates the skin; the decision to use topical amphotericin B should be made based on expert consultation.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold> There is limited clinical data regarding the&#x000a0;effect of hepatic impairment on the pharmacokinetics of amphotericin B.</p>
        <p><bold>Renal impairment:</bold> Nephrotoxicity is higher with amphotericin B deoxycholate than with lipid-based formulations.</p>
        <p><bold>Pregnancy Considerations:</bold>&#x000a0;Amphotericin B&#x000a0;should be used during pregnancy only if indicated. According to IDSA guidelines, amphotericin B is the&#x000a0;drug of choice&#x000a0;for invasive candidiasis in&#x000a0;pregnancy.<xref ref-type="bibr" rid="article-17480.r9">[9]</xref> Using ideal body weight instead of total body weight&#x000a0;can&#x000a0;reduce potential adverse effects on the fetus. Liposomal amphotericin B is&#x000a0;preferred&#x000a0;due to its minimal risk of teratogenicity during pregnancy.<xref ref-type="bibr" rid="article-17480.r21">[21]</xref></p>
        <p><bold>Breastfeeding Considerations:</bold> Limited information is available regarding the&#x000a0;presence of amphotericin B in human milk. However, due to its high protein binding, large molecular weight, and poor oral absorption, the use of amphotericin B during lactation is considered probably safe. Therefore, most experts consider it acceptable for use in breastfeeding mothers.<xref ref-type="bibr" rid="article-17480.r22">[22]</xref></p>
        <p><bold>Pediatric Patients:</bold>&#x000a0;The safety and efficacy of amphotericin B in patients &#x0003c;1 month of age have not been established. However, successful treatment of systemic fungal infections in pediatric patients with amphotericin B deoxycholate has been observed without any unusual&#x000a0;adverse effects. Amphotericin B lipid complex (ABLC) has shown efficacy in treating hepatosplenic candidiasis. Liposomal amphotericin B has demonstrated positive outcomes in pediatric patients with systemic fungal infections or visceral leishmaniasis.<xref ref-type="bibr" rid="article-17480.r23">[23]</xref></p>
        <p><bold>Older&#x000a0;Patients:</bold>&#x000a0;In older adults, amphotericin B lipid complex has been administered at a dose of 5 mg/kg/d, and no significant unexpected adverse events were reported.</p>
      </sec>
      <sec id="article-17480.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>About 80% of the patients will develop infusion-related adverse effects or nephrotoxicity. Amphotericin B interacts with cholesterol in human cell membranes, which is responsible for its toxicity. The common adverse effects of amphotericin B include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypokalemia&#x000a0;<xref ref-type="bibr" rid="article-17480.r24">[24]</xref></p>
          </list-item>
          <list-item>
            <p>Hypomagnesemia&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Anaphylaxis</p>
          </list-item>
          <list-item>
            <p>Nephrotoxicity: Renal toxicity correlates with conventional amphotericin B use and can lead to renal failure and the requirement for dialysis. But the azotemia often stabilizes with therapy, and&#x000a0;renal damage&#x000a0;is reversible after discontinuation of&#x000a0;amphotericin B.&#x000a0;Avoiding&#x000a0;concomitant use of other nephrotoxic agents and appropriate hydration&#x000a0;with normal saline may significantly decrease the likelihood and severity of azotemia associated with amphotericin B. Systematic review and meta-analysis suggests that liposomal formulation is associated with substantially lower nephrotoxicity compared to conventional amphotericin B.<xref ref-type="bibr" rid="article-17480.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Other potential uncommon&#x000a0;adverse effects include demyelinating encephalopathy in patients with bone marrow transplants with total body irradiation or receiving cyclosporine.</p>
          </list-item>
          <list-item>
            <p>The long-term administration is associated with normochromic, normocytic anemia due to low erythropoietin concentrations.<xref ref-type="bibr" rid="article-17480.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p>Fever, headache, chills, hypotension, tachypnea, and vomiting typically occur within 1 to 3 hours after initiating an intravenous infusion of amphotericin B. These reactions are usually more&#x000a0;encountered with the initial doses.<xref ref-type="bibr" rid="article-17480.r27">[27]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Antineoplastic agents:</bold> Concurrent use may increase the risk of bronchospasm, nephrotoxicity, and hypotension. Caution is advised when using antineoplastic agents (especially nitrogen mustard)&#x000a0;with amphotericin B.</p>
          </list-item>
          <list-item>
            <p><bold>Corticosteroids:</bold> Concomitant steroid use should be reconsidered to reduce the risk of hypokalemia.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Digoxin:</bold> Hypokalemia can potentiate digoxin toxicity and can cause rhabdomyolysis. Monitoring of serum potassium levels is necessary, and electrolytes should be replenished.<xref ref-type="bibr" rid="article-17480.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Flucytosine:</bold> Simultaneous use of amphotericin B may increase the toxicity of flucytosine, possibly affecting its cellular uptake and renal excretion. Careful monitoring is required when using amphotericin B and flucytosine together.</p>
          </list-item>
          <list-item>
            <p><bold>Azoles (ketoconazole, miconazole, clotrimazole, fluconazole):</bold> In vitro and&#x000a0;preclinical studies suggest that imidazoles may induce fungal resistance to amphotericin B. Combination therapy should be&#x000a0;administered with caution, especially in immunocompromised patients.<xref ref-type="bibr" rid="article-17480.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Nephrotoxic drugs:</bold> Drugs such as aminoglycosides, cyclosporine, and pentamidine may increase the risk of&#x000a0;nephrotoxicity when used concomitantly with amphotericin B.&#x000a0;Monitoring of renal function is required.<xref ref-type="bibr" rid="article-17480.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Skeletal muscle relaxants:</bold> Amphotericin B-induced hypokalemia can&#x000a0;increase the effect of skeletal muscle relaxants like tubocurarine. Use with caution.</p>
          </list-item>
          <list-item>
            <p><bold>Leukocyte transfusions:</bold> Simultaneous infusion of amphotericin B and granulocytes correlates with acute pulmonary reactions, and clinicians should avoid the combination.<xref ref-type="bibr" rid="article-17480.r30">[30]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Laboratory Interaction</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Liposomal amphotericin B can&#x000a0;cause pseudo-hyperphosphatemia due to interference with&#x000a0;the PHOSm assay.<xref ref-type="bibr" rid="article-17480.r31">[31]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17480.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Absolute contraindications include a history of anaphylactic reaction to amphotericin B.<xref ref-type="bibr" rid="article-17480.r32">[32]</xref></p>
        <p>
<bold>Boxed Warning</bold>
</p>
        <p>Use caution to prevent overdosage of amphotericin B, as it can lead to cardiopulmonary arrest.<xref ref-type="bibr" rid="article-17480.r33">[33]</xref>&#x000a0;The product name and&#x000a0;formulation should be verified, especially if the prescribed dose of amphotericin B exceeds the suggested maximum of 1.5 mg/kg. Amphotericin B is primarily indicated for treating progressive and potentially life-threatening fungal infections. Amphotericin B should not be in patients with normal neutrophil counts to treat noninvasive fungal diseases, such as vaginal candidiasis, oral thrush, and esophageal candidiasis.</p>
        <p>
<bold>Precautions</bold>
</p>
        <p>Do not administer amphotericin B by&#x000a0;rapid intravenous infusion due to the possibility of hypotension, hypokalemia, arrhythmias, and shock.&#x000a0;Amphotericin B use has been linked to leukoencephalopathy; total body irradiation increases the risk.<xref ref-type="bibr" rid="article-17480.r34">[34]</xref></p>
      </sec>
      <sec id="article-17480.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Monitoring amphotericin B concentrations in the serum or CSF is of little value because the relationships between plasma and tissue concentrations and clinical efficacy or toxicity have not been adequately researched. Monitoring is a recommendation to evaluate for the presence of&#x000a0;adverse effects.&#x000a0;Initially, a daily electrolyte panel, including potassium and magnesium concentrations, is required until the dose increases to its therapeutic concentration, and after that, weekly electrolyte concentrations are sufficient.<xref ref-type="bibr" rid="article-17480.r35">[35]</xref></p>
        <p>Clinicians should obtain potassium concentrations immediately&#x000a0;if the patient presents with signs of hypokalemia, such as muscle weakness, cramps, drowsiness, or ECG changes of hypokalemia. Renal function should also be monitored closely due to the risk of nephrotoxicity and distal renal tubular acidosis.<xref ref-type="bibr" rid="article-17480.r35">[35]</xref></p>
      </sec>
      <sec id="article-17480.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Amphotericin exhibits infusion-related toxicity, which accounts for its extended administration times. Infuse slowly over 3 hours; rapid infusion can cause cardiotoxicity. Amphotericin B deoxycholate overdose can cause ventricular arrhythmias and bradycardia in&#x000a0;patients with preexisting cardiac conditions.<xref ref-type="bibr" rid="article-17480.r36">[36]</xref></p>
        <p>Due to the similarity of mammalian and fungal membranes, which both contain sterols (the therapeutic target for amphotericin B), amphotericin B can exhibit cellular toxicity.&#x000a0;In the suspected overdose of amphotericin B, treatment should be discontinued. Supportive therapy should be administered as required. Amphotericin B and its formulations are not effectively removed by dialysis.</p>
      </sec>
      <sec id="article-17480.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Healthcare professionals, including physicians and advanced practice practitioners prescribing amphotericin B, should know its indications, administration, and&#x000a0;adverse effects. Close to 80% of the patients will develop either infusion-related or renal toxicity. Before the infusion, consider pretreatment with acetaminophen, diphenhydramine, or hydrocortisone to attenuate&#x000a0;adverse effects. Meperidine treatment may decrease the duration of rigors.<xref ref-type="bibr" rid="article-17480.r11">[11]</xref>&#x000a0;Following infusion, the patient's renal function requires periodic monitoring.</p>
        <p>Given the drug's interaction and adverse event profile, it is unsurprising that amphotericin B use is cautiously used. However, prescribers may need to employ it for recalcitrant infections, and consultation with the pharmacist is necessary to ensure no drug-drug interactions exist or that a different agent might achieve the desired therapeutic result. Nurses also need to understand the side effect profile of this drug and the potential for infusion reactions; if there are any concerns, the nursing staff should immediately alert the prescribing clinician. A robust, collaborative, interprofessional healthcare team effort involving physicians, infectious disease specialists, advanced practice practitioners, nurses, and pharmacists must achieve desired patient outcomes with minimal adverse effects.</p>
      </sec>
      <sec id="article-17480.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17480&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17480">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17480/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17480">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17480.s11">
        <title>References</title>
        <ref id="article-17480.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vasileiou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Apsemidou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vyzantiadis</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Tragiannidis</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Invasive candidiasis and candidemia in pediatric and neonatal patients: A review of current guidelines.</article-title>
            <source>Curr Med Mycol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>28</fpage>
            <page-range>28-33</page-range>
            <pub-id pub-id-type="pmid">30619967</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jansook</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>F&#x000fc;l&#x000f6;p</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ritthidej</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>Amphotericin B loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carrier (NLCs): physicochemical and solid-solution state characterizations.</article-title>
            <source>Drug Dev Ind Pharm</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>45</volume>
            <issue>4</issue>
            <fpage>560</fpage>
            <page-range>560-567</page-range>
            <pub-id pub-id-type="pmid">30632399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ullmann</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Sanz</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Tramarin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Gerlach</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Krobot</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Gerth</surname>
                <given-names>WC</given-names>
              </name>
              <collab>Longitudinal Evaluation of Antifungal Drugs (LEAD I) Investigators</collab>
            </person-group>
            <article-title>Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries.</article-title>
            <source>Clin Infect Dis</source>
            <year>2006</year>
            <month>Aug</month>
            <day>15</day>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>e29</fpage>
            <page-range>e29-38</page-range>
            <pub-id pub-id-type="pmid">16838223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamill</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Amphotericin B formulations: a comparative review of efficacy and toxicity.</article-title>
            <source>Drugs</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>73</volume>
            <issue>9</issue>
            <fpage>919</fpage>
            <page-range>919-34</page-range>
            <pub-id pub-id-type="pmid">23729001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kauffman</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Bustamante</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Pappas</surname>
                <given-names>PG</given-names>
              </name>
              <collab>Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2007</year>
            <month>Nov</month>
            <day>15</day>
            <volume>45</volume>
            <issue>10</issue>
            <fpage>1255</fpage>
            <page-range>1255-65</page-range>
            <pub-id pub-id-type="pmid">17968818</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maertens</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pagano</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Azoulay</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Warris</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Liposomal amphotericin B-the present.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2022</year>
            <month>Nov</month>
            <day>25</day>
            <volume>77</volume>
            <issue>Suppl_2</issue>
            <fpage>ii11</fpage>
            <page-range>ii11-ii20</page-range>
            <pub-id pub-id-type="pmid">36426672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patterson</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Denning</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Fishman</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Hadley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Herbrecht</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kontoyiannis</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Marr</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Steinbach</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Wingard</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2016</year>
            <month>Aug</month>
            <day>15</day>
            <volume>63</volume>
            <issue>4</issue>
            <fpage>433</fpage>
            <page-range>433-42</page-range>
            <pub-id pub-id-type="pmid">27481947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aronson</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Herwaldt</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Libman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pearson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lopez-Velez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Weina</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Carvalho</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Ephros</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jeronimo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Magill</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).</article-title>
            <source>Clin Infect Dis</source>
            <year>2016</year>
            <month>Dec</month>
            <day>15</day>
            <volume>63</volume>
            <issue>12</issue>
            <fpage>e202</fpage>
            <page-range>e202-e264</page-range>
            <pub-id pub-id-type="pmid">27941151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pappas</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Kauffman</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Andes</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Clancy</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Marr</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Ostrosky-Zeichner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Reboli</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Schuster</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Vazquez</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Zaoutis</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Sobel</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2016</year>
            <month>Feb</month>
            <day>15</day>
            <volume>62</volume>
            <issue>4</issue>
            <fpage>e1</fpage>
            <page-range>e1-50</page-range>
            <pub-id pub-id-type="pmid">26679628</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shikanai-Yasuda</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Mendes</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Colombo</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Queiroz-Telles</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kono</surname>
                <given-names>ASG</given-names>
              </name>
              <name>
                <surname>Paniago</surname>
                <given-names>AMM</given-names>
              </name>
              <name>
                <surname>Nathan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Valle</surname>
                <given-names>ACFD</given-names>
              </name>
              <name>
                <surname>Bagagli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Benard</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Teixeira</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Silva-Vergara</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Cavalcante</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Durlacher</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Khoury</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Camargo</surname>
                <given-names>ZP</given-names>
              </name>
              <name>
                <surname>Moretti</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Brazilian guidelines for the clinical management of paracoccidioidomycosis.</article-title>
            <source>Rev Soc Bras Med Trop</source>
            <year>2017</year>
            <season>Sep-Oct</season>
            <volume>50</volume>
            <issue>5</issue>
            <fpage>715</fpage>
            <page-range>715-740</page-range>
            <pub-id pub-id-type="pmid">28746570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cavassin</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Ba&#x000fa;-Carneiro</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Vilas-Boas</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Queiroz-Telles</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Sixty&#x000a0;years of Amphotericin&#x000a0;B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections.</article-title>
            <source>Infect Dis Ther</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>115</fpage>
            <page-range>115-147</page-range>
            <pub-id pub-id-type="pmid">33523419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pruthi</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>When to Initiate Antifungal Treatment in COVID-19 Patients with Secondary Fungal Co-infection.</article-title>
            <source>Curr Clin Microbiol Rep</source>
            <year>2022</year>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>60</fpage>
            <page-range>60-68</page-range>
            <pub-id pub-id-type="pmid">36345368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al Balushi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khamis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Klaassen</surname>
                <given-names>CHW</given-names>
              </name>
              <name>
                <surname>Gangneux</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Van Hellemond</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Double Infection With <italic>Leishmania tropica</italic> and <italic>L. major</italic> in an HIV Patient Controlled With High Doses of Amphotericin B.</article-title>
            <source>Open Forum Infect Dis</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>5</volume>
            <issue>12</issue>
            <fpage>ofy323</fpage>
            <pub-id pub-id-type="pmid">30619911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rybak</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Fortwendel</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>Emerging threat of triazole-resistant Aspergillus fumigatus.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2019</year>
            <month>Apr</month>
            <day>01</day>
            <volume>74</volume>
            <issue>4</issue>
            <fpage>835</fpage>
            <page-range>835-842</page-range>
            <pub-id pub-id-type="pmid">30561652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Groll</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Rijnders</surname>
                <given-names>BJA</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Adler-Moore</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Br&#x000fc;ggemann</surname>
                <given-names>RJM</given-names>
              </name>
            </person-group>
            <article-title>Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B.</article-title>
            <source>Clin Infect Dis</source>
            <year>2019</year>
            <month>May</month>
            <day>02</day>
            <volume>68</volume>
            <issue>Suppl 4</issue>
            <fpage>S260</fpage>
            <page-range>S260-S274</page-range>
            <pub-id pub-id-type="pmid">31222253</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adler-Moore</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Br&#x000fc;ggemann</surname>
                <given-names>RJM</given-names>
              </name>
              <name>
                <surname>Rijnders</surname>
                <given-names>BJA</given-names>
              </name>
              <name>
                <surname>Groll</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B.</article-title>
            <source>Clin Infect Dis</source>
            <year>2019</year>
            <month>May</month>
            <day>02</day>
            <volume>68</volume>
            <issue>Suppl 4</issue>
            <fpage>S244</fpage>
            <page-range>S244-S259</page-range>
            <pub-id pub-id-type="pmid">31222254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bekersky</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Fielding</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Dressler</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Buell</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2002</year>
            <month>Mar</month>
            <volume>46</volume>
            <issue>3</issue>
            <fpage>828</fpage>
            <page-range>828-33</page-range>
            <pub-id pub-id-type="pmid">11850268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lestrade</surname>
                <given-names>PPA</given-names>
              </name>
              <name>
                <surname>Meis</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Melchers</surname>
                <given-names>WJG</given-names>
              </name>
              <name>
                <surname>Verweij</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Triazole resistance in Aspergillus fumigatus: recent insights and challenges for patient management.</article-title>
            <source>Clin Microbiol Infect</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>25</volume>
            <issue>7</issue>
            <fpage>799</fpage>
            <page-range>799-806</page-range>
            <pub-id pub-id-type="pmid">30580035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sun</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Lortholary</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Dromer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Forrest</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Lyon</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Somani</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>del Busto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pruett</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Sifri</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Limaye</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Klintmalm</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Pursell</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stosor</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Dowdy</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Munoz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kalil</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Garcia-Diaz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Orloff</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>House</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Houston</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wray</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Huprikar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Humar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Razonable</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Husain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis.</article-title>
            <source>Clin Infect Dis</source>
            <year>2009</year>
            <month>Dec</month>
            <day>01</day>
            <volume>49</volume>
            <issue>11</issue>
            <fpage>1721</fpage>
            <page-range>1721-8</page-range>
            <pub-id pub-id-type="pmid">19886800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Current treatments against mucormycosis and future directions.</article-title>
            <source>PLoS Pathog</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>18</volume>
            <issue>10</issue>
            <fpage>e1010858</fpage>
            <pub-id pub-id-type="pmid">36227854</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Grady</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>McManus</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Briggs</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Azar</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Topal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>Dosing implications for liposomal amphotericin B in pregnancy.</article-title>
            <source>Pharmacotherapy</source>
            <year>2023</year>
            <month>May</month>
            <volume>43</volume>
            <issue>5</issue>
            <fpage>452</fpage>
            <page-range>452-462</page-range>
            <pub-id pub-id-type="pmid">36862037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r22">
          <label>22</label>
          <element-citation publication-type="book">
            <chapter-title>Amphotericin B</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>3</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">30000380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pandey</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pal</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Siddiqui</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Rabi Das</surname>
                <given-names>VN</given-names>
              </name>
              <name>
                <surname>Murti</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lal</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Babu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis in Children and Adolescents at a Tertiary Care Center in Bihar, India.</article-title>
            <source>Am J Trop Med Hyg</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>97</volume>
            <issue>5</issue>
            <fpage>1498</fpage>
            <page-range>1498-1502</page-range>
            <pub-id pub-id-type="pmid">29016288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Usami</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kanematsu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakashima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Matsuoka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yoshimura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sugiyama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Teramachi</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of hypokalemia and potassium supplementation during administration of liposomal-amphotericin B.</article-title>
            <source>Exp Ther Med</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>941</fpage>
            <page-range>941-946</page-range>
            <pub-id pub-id-type="pmid">24669255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Botero Aguirre</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Restrepo Hamid</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2015</year>
            <month>Nov</month>
            <day>23</day>
            <volume>2015</volume>
            <issue>11</issue>
            <fpage>CD010481</fpage>
            <pub-id pub-id-type="pmid">26595825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaish</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Ansari</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>Amphotericin B induced pancytopenia.</article-title>
            <source>J Family Med Prim Care</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>11</volume>
            <issue>9</issue>
            <fpage>5692</fpage>
            <page-range>5692-5695</page-range>
            <pub-id pub-id-type="pmid">36505588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laniado-Labor&#x000ed;n</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cabrales-Vargas</surname>
                <given-names>MN</given-names>
              </name>
            </person-group>
            <article-title>Amphotericin B: side effects and toxicity.</article-title>
            <source>Rev Iberoam Micol</source>
            <year>2009</year>
            <month>Dec</month>
            <day>31</day>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>223</fpage>
            <page-range>223-7</page-range>
            <pub-id pub-id-type="pmid">19836985</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trejtnar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mand&#x000ed;kov&#x000e1;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ko&#x0010d;&#x000ed;ncov&#x000e1;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Volkov&#x000e1;</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Renal handling of amphotericin B and amphotericin B-deoxycholate and potential renal drug-drug interactions with selected antivirals.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>58</volume>
            <issue>10</issue>
            <fpage>5650</fpage>
            <page-range>5650-7</page-range>
            <pub-id pub-id-type="pmid">24957831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dobrek</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>A Synopsis of Current Theories on Drug-Induced Nephrotoxicity.</article-title>
            <source>Life (Basel)</source>
            <year>2023</year>
            <month>Jan</month>
            <day>24</day>
            <volume>13</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">36836682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Collazos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mayo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ibarra</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary reactions during treatment with amphotericin B: review of published cases and guidelines for management.</article-title>
            <source>Clin Infect Dis</source>
            <year>2001</year>
            <month>Oct</month>
            <day>01</day>
            <volume>33</volume>
            <issue>7</issue>
            <fpage>E75</fpage>
            <page-range>E75-82</page-range>
            <pub-id pub-id-type="pmid">11528589</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bohm</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Hoover</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Wahlquist</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Velez</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Case-control study and case series of pseudohyperphosphatemia during exposure to liposomal amphotericin B.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>59</volume>
            <issue>11</issue>
            <fpage>6816</fpage>
            <page-range>6816-23</page-range>
            <pub-id pub-id-type="pmid">26282423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nath</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Basher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Harada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sarkar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Selim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maude</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Noiri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Faiz</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Immediate hypersensitivity reaction following liposomal amphotericin-B (AmBisome) infusion.</article-title>
            <source>Trop Doct</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>44</volume>
            <issue>4</issue>
            <fpage>241</fpage>
            <page-range>241-2</page-range>
            <pub-id pub-id-type="pmid">25139411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drewett</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Copaescu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>DeLuca</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Trubiano</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Asystolic cardiac arrest following liposomal amphotericin&#x000a0;B infusion: anaphylaxis or compliment activation-related pseudoallergy?</article-title>
            <source>Allergy Asthma Clin Immunol</source>
            <year>2021</year>
            <month>Jul</month>
            <day>29</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>80</fpage>
            <pub-id pub-id-type="pmid">34325715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Case report: Reversible encephalopathy associated with liposomal amphotericin B in a patient with cryptococcal meningitis.</article-title>
            <source>Front Neurol</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>1019137</fpage>
            <pub-id pub-id-type="pmid">36438952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palmer</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Kelepouris</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Clegg</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Renal Tubular Acidosis and Management Strategies: A Narrative Review.</article-title>
            <source>Adv Ther</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>949</fpage>
            <page-range>949-968</page-range>
            <pub-id pub-id-type="pmid">33367987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17480.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burke</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Finkel</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Samuels</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Foringer</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Acute amphotericin B overdose.</article-title>
            <source>Ann Pharmacother</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>40</volume>
            <issue>12</issue>
            <fpage>2254</fpage>
            <page-range>2254-9</page-range>
            <pub-id pub-id-type="pmid">17090724</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
